Cabazitaxel versus enzalutamide/abiraterone in CARD eligible mCRPC patients with or without germline HRR defects

Autor: Amaia Hernandez, Elena Castro, Elena Almagro, Nuria Romero-Laorden, R. Villatoro, Casilda Llacer Perez, Carlo Cattrini, David Lorente, Jose Maria M. Piulats Rodriguez, Enrique Gallardo Diaz, Pablo Borrega, Nuria Lainez, Rebeca Lozano, Pedro P. López-Casas, Francesca Vitrone, Ana Medina, David Olmos, Javier Puente, Alejo Rodriguez-Vida, L. Rivera
Rok vydání: 2020
Předmět:
Zdroj: Journal of Clinical Oncology. 38:5554-5554
ISSN: 1527-7755
0732-183X
DOI: 10.1200/jco.2020.38.15_suppl.5554
Popis: 5554 Background: The CARD trial proved that in mCPRC patients (pts), previously treated with docetaxel and an androgen-receptor signaling inhibitor (ARSi), cabazitaxel (CBZ) significantly improves progression-free (PFS) and Overall Survival (OS) compared with the alternative ARSi. Concurrently, the PROFOUND study showed the superiority of olaparib vs. ARSi in pts with similar prior treatment history and genetic alterations in Homologus Recombination DNA repair related genes (HRR). Methods: PROREPAIR-B (NCT03075735) is a prospective study which aimed to demonstrate the prognostic role of germline deleterious mutations in (g)HRR genes and the benefit of first (1L), second (2L) and subsequent therapy lines for mCRPC. Outcomes with 1-2L have been previously reported. Here we evaluated radiographic (r)-PFS, clinical (c)-PFS, and OS in PROREPAIR-B pts who meet CARD study eligibility criteria and who received CBZ and/or ARSi. Survival analysis were performed using Kaplan Meier method and Cox regression models. Results: 95 out of 419 mCRPC pts included in PROREPAIR-B meet CARD eligibility criteria and received CBZ (n=60) or ARSi (n=35) including 14 gHRR carriers, 8/6 treated with CBZ/ARSi, respectively. Visceral metastases were more frequent among pts treated with CBZ (p=0.01). ECOG 2, M1 at diagnosis, Abiraterone as 1st ARSi and prior radiographic PD (all p
Databáze: OpenAIRE
Externí odkaz: